Skip to main content
Fig. 5 | BMC Cancer

Fig. 5

From: Development of acquired resistance to lapatinib may sensitise HER2-positive breast cancer cells to apoptosis induction by obatoclax and TRAIL

Fig. 5

The effect of TRAIL ligand (5 ng/mL) in combination with obatoclax on proliferation of (a) SKBR3-L and (b) SKBR3-Par cells in a 5-day proliferation assay. Error bars represent the standard deviation of triplicate independent experiments. ‘*’ indicates a p value of < 0.05 as calculated by Student’s t-test

Back to article page